391-83-3

Basic information

• Product Name: 7-FLUORO-4-HYDROXYQUINOLINE
• Synonyms: 4-Hydroxy-7-fluoroquinoline;7-Fluoro--Hydroxyquinoline;BUTTPARK 13\01-66;7-FLUOROQUINOLINE-4-OL;7-FLUORO-4-HYDROXYQUINOLINE;7-FLUORO-4-QUINOLINOL
• CAS NO: 391-83-3
• Molecular Formula: C₉H₆FNO
• Molecular Weight: 163.15
• Mol File: 391-83-3.mol

Chemical Properties

• Boiling Point: 262.4 °C at 760 mmHg
• Flash Point: 112.5 °C
• Appearance: /
• Density: 1.291 g/cm³
• Vapor Pressure: 0.0109mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: 7-FLUORO-4-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-FLUORO-4-HYDROXYQUINOLINE(391-83-3)
• EPA Substance Registry System: 7-FLUORO-4-HYDROXYQUINOLINE(391-83-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 391-83-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Fluoro-4-hydroxyquinoline is used as an antimicrobial agent for its potent antibacterial and antifungal properties, playing a crucial role in the development of new pharmaceutical formulations to combat resistant strains of bacteria and fungi.
Used in Research and Development:
In the field of research, 7-fluoro-4-hydroxyquinoline is utilized as a key intermediate in the synthesis of other organic compounds, contributing to the advancement of chemical sciences and the creation of innovative products with diverse applications.
Used in Antibacterial Agent Development:
7-Fluoro-4-hydroxyquinoline is employed as a precursor in the development of new antibacterial agents, given its demonstrated effectiveness against a range of bacterial species, making it a valuable asset in the ongoing battle against antibiotic resistance.

InChI:InChI=1/C9H6FNO/c10-6-1-2-7-8(5-6)11-4-3-9(7)12/h1-5H,(H,11,12)

Upstream product

• 372-19-0 meta-fluoroaniline 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 63463-20-7 7-Fluoro-4-hydroxyquinoline-3-carboxylic acid 
• 26832-95-1 diethyl 2-(((3-fluorophenyl)amino)methylene)malonate 
• 26892-97-7 ethyl 7-fluoro-4-hydroxy-3-quinolinecarboxylate 
• 122-51-0 orthoformic acid triethyl ester 
• 183057-56-9 7-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 
• 26892-97-7 7-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid ethyl ester 
• 159305-15-4 1-(2-Amino-4-fluorophenyl)ethanone 
• 109-94-4 formic acid ethyl ester 
• 25063-54-1 5-(((3-fluorophenyl)amino)methylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 138716-20-8 (E)-3-(dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 391-82-2 4-Chloro-7-fluoroquinoline 
• 442-96-6 rac-N¹,N¹-diethyl-N⁴-(7-fluoroquinolin-4-yl)pentane-1,4-diamine 
• 256923-33-8 7-fluoro-3-nitro-4-quinolinol 
• 86-98-6 4,7-dichloroquinoline 
• 26707-52-8 7-chloro-4-methoxyquinoline 
• 5448-52-2 7-chloro-4-ethoxyquinoline 

Relevant articles and documents

3,6-DISUBSTITUTED-2-PYRIDINALDOXIME SCAFFOLDS

The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: wherein R1, R2 and -X-Y- have specific definitions. It also relates to the use of such a compound as reactivator of acetylcholinesterase for treating organophosphorous nerve agents poisoning; and to a process for preparing it.

Design, synthesis and biological evaluation of new quinoline derivatives as potential antitumor agents

A series of new quinoline derivatives was designed, synthesized and evaluated for their antiproliferative activity. The results demonstrated that compounds 11p, 11s, 11v, 11x and 11y exhibited potent antiproliferative activity with IC50 value of lower than 10 μM against seven human tumor cell lines, and N-(3-methoxyphenyl)-7- (3-phenylpropoxy)quinolin-4-amine 11x was found to be the most potent antiproliferative agent against HCT-116, RKO, A2780 and Hela cell lines with an IC50 value of 2.56, 3.67, 3.46 and 2.71 μM, respectively. The antitumor efficacy of the representative compound 11x in mice was also evaluated, and the results showed that compound 11x effectively inhibited tumor growth and decreased tumor weight in animal models. Further investigation on mechanism of action indicated that compound 11x could inhibit colorectal cancer growth through ATG5-depenent autophagy pathway. Therefore, these quinoline derivatives are a new class of molecules that have the potential to be developed as new antitumor drugs.

Inhibitor IDO and application thereof (by machine translation)

The invention belongs to the technical field of medicines, and (I) particularly relates to a compound or a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a ring A, a B ring R, a ring, and a ring of the compound shown in formula (I

For antibacterial chlorine oxygen kui derivatives

The invention relates to an oxo-quinoline derivative with activity of resisting bacterial infection relevant diseases such as helicobacter pylori (Hp) infection disease. The invention specifically relates to a compound as shown in formula I in the specification, and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is selected from hydrogen, -C alkyl, -C alkenyl, -C alkynyl, or -C alkyl-phenyl, and the alkyl, alkenyl, alkynyl and phenyl can be randomly substituted by halogen, nitro, cyan, hydroxyl, -C alkoxy and phenyl; R is selected from hydrogen, -CONHR and -COOR, R and R are independently selected from -C alkyl and -C alkyl amino, and the amino is randomly substituted by one to two -C alkyls; R is selected from halogen, -C alkoxy, morpholinyl or piperazinyl.

With anti-tumor activity of chlorine oxygen kui derivatives

The invention relates to a chloroxoquinoline derivatives with anti-tumor activity and specifically relates to compounds of a formula I as shown in the specification and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1 is selected from hydrogen, -C1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl and -C1-6 alkyl-phenyl, and the alkyl, the alkenyl, the alkynyl and the phenyl can be optionally substituted by halogens, nitryl, cyan, hydroxyl, -C1-6 alkoxy and phenyl; R3 is selected from hydrogen, -CONHR31 and -COOR32, the R31 and the R32 are independently selected from -C1-6 alkyl and -C1-6 alkylamino, respectively, and the amino can be optionally substituted by 1 to 2 -C1-6 alkyls; R7 is selected from halogens, -C1-6 alkoxy, morpholinyl and piperazine; the formula I is as shown in the specification.

Co(III)-Catalyzed Enaminone-Directed C-H Amidation for Quinolone Synthesis

We report herein the development of a Co(III)-catalyzed enaminone-directed C-H amidation method for synthetic access to quinolones, an important heterocyclic scaffold for diverse pharmaceutically active structures. The C-H coupling with dioxazolones and subsequent deacylation of an installed amide group allow consecutive C-N coupling generation of quinolones with wide-ranging compatible substituent patterns.

Synthesis and anti-tumor activities of 4-anilinoquinoline derivatives

Twenty-two 7-fluoro (or 8-methoxy)-4-anilinoquinolines compounds were designed and synthesized as potentially potent and selective antitumor inhibitors. All the prepared compounds were evaluated for their in vitro antiproliferative activities against the HeLa and BGC823 cell lines. Ten compounds (1a-g; 2c; 2e and 2i) exhibited excellent antitumor activity superior to that of gefitinib. Among the ten compounds; seven (1a-c; 1e-1g and 2i) displayed excellent selectivity for BGC823 cells. In particular; 1f and 2i exhibited potent cytotoxic activities against HeLa cells and BGC823 cells with better IC50 values than gefitinib.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINOLINE DERIVATIVES FOR TREATING CANCER

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

Microwave-assisted synthesis of fluoroquinolones and their nucleosides as inhibitors of HIV integrase

Six fluoroquinolone ribonucleosides were synthesized by using microwave irradiation starting from fluoroanilines. In most cases the microwave application proved superior in time and yield, especially the one step decarboxylation of the carboxyquinolone esters 3a-3c and the Vorbrueggen glycosylation. The former led to the new type of fluoroquinolone ribosides 8a-8c. Compound 8c in the crystal structure showed C3′-endo and anti conformation. The nucleosides were examined, but found inactive against the replication of HIV-1(IIIB) in cell culture, while they were toxic for the cells at a 50% cytotoxic concentration ranging from 31 to >125 μg/ml. But measurements of the inhibitory effects against HIV-1 integrase enzymatic activity showed an interesting activity for compound 8c.